Ivermectin-loaded microparticles for parenteral sustained release: In vitro characterization and effect of some formulation variables

Journal of Microencapsulation

Volumn 27, Issue 7, 2010, Pages 609-617

  Camargo, J A ^a   Sapin, A ^a   Daloz, D ^a   Maincent, P ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Ivermectin; Microparticles; PLA; PLGA; PVP; Sustained release

Indexed keywords

IVERMECTIN; POLYGLACTIN; POLYLACTIC ACID; POVIDONE;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; EMULSION; EVAPORATION; HYDROPHILICITY; IN VITRO STUDY; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EMULSIONS; INSECTICIDES; IVERMECTIN; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; POLYESTERS; POLYGLACTIN 910; POLYGLYCOLIC ACID; POVIDONE; SOLVENTS; TIME FACTORS; X-RAY DIFFRACTION;

EID: 77957810263     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2010.501397     Document Type: Article

References (40)

1. Bassissi F, Lespine A, Alvinerie M. Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration. Parasitol Res, 2006;98:244-9.
2. Benoit JP, Courteille F, Thies C. A physicochemical study of the morphology of progesterone-loaded poly (D,L-lactide) microspheres. Int J Pharm, 1986;29:95-102.
3. Bodmeier R, Chen H. Preparation and characterization of microspheres containing the anti-inflammatory agents, indomethacin, ibuprofen, and ketoprofen. J Control Release, 1989;10:167-75.
4. Bodmeier R, McGinity JW. Solvent selection in the preparation ofpoly(DLLactide) microspheres prepared by the solvent evaporation method. Int J Pharm, 1988;43:179-86.
5. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm, 1995;116:1-9.
6. Chhabra S, Sachdeva V, Singh S. Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system. Int J Pharm, 2007;342:72-7.
7. Clark SL, Crowley AJ, Schmidt PG, Donoghue AR, Piche CA. Long-term delivery of ivermectin by use of poly(D,L-lactic-co-glycolic)acid microparticles in dogs. Am J Vet Res, 2004;65:752-7.
8. Dunne M, Corrigan I, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials, 2000;21:1659-68.
9. Frank A, Rath SK, Venkatraman SS. Controlled release from bioerodible polymers: effect of drug type and polymer composition. J Control Release, 2005;102:333-44.
10. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm, 2004;282:1-18.
11. Gokbulut C, Karademir U, Boyacioglu M, McKellar QA. Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs. Vet Parasitol, 2006;135:347-54.
12. Gonzalez Canga A, Sahagun Prieto AM, Jose Diez Liebana M, Martinez NF, Vega MS, Vieitez JJ. The pharmacokinetics and metabolism ofivermectin in domestic animal species. Vet J, 2009;179:25-37.
13. Hasan AS, Socha M, Lamprecht A, Ghazouani FE, Sapin A, Hoffman M, Maincent P, Ubrich N. Effect of the microencapsulation of nanoparticles on the reduction of burst release. Int J Pharm, 2007;344:53-61.
14. Hausberger AG, DeLuca PP. Characterization of biodegradable poly(D,Llactide-co-glycolide) polymers and microspheres. J Pharm Biomed Anal, 1995;13:747-60.
15. Hennessy DR. Modifying the formulation or delivery mechanism to increase the activity of anthelmintic compounds. Vet Parasitol, 1997;72:367-82; discussion 382-90.
16. Herrmann J, Bodmeier R. The effect of particle microstructure on the somatostatin release from poly(lactide) microspheres prepared by a W/O/W solvent evaporation method. J Control Release, 1995;36:63-71.
17. Jaraswekin S, Prakongpan S, Bodmeier R. Effect of poly(lactide-co- glycolide) molecular weight on the release of dexamethasone sodium phosphate from microparticles. J Microencapsul, 2007;24:117-28.
18. Kim JE, Kim SR, Lee SH, Lee CH, Kim DD. The effect of pore formers on the controlled release of cefadroxil from a polyurethane matrix. Int J Pharm, 2000;201:29-36.
19. Klose D, Siepmann F, Elkharraz K, Krenzlin S, Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int J Pharm, 2006;314:198-206.
20. Klose D, Siepmann F, Elkharraz K, Siepmann J. PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int J Pharm, 2008;354:95-103.
21. Kubin A, Loew HG, Burner U, Jessner G, Kolbabek H, Wierrani F. How to make hypericin water-soluble. Pharmazie, 2008;63:263-9.
22. Liu J, Chang Z, Sun X, Shen S, Lei C, Liu H. Impurity effects on the crystallization of avermectin B1a. J. Crystal Growth, 2006;291:448-54.
23. Loffler D, Ternes TA. Determination ofacidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry. J Chromatogr A, 2003;1021:133-44.
24. Luan X, Bodmeier R. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly(lactide-co-glycolide) microparticles. Eur J Pharm Biopharm, 2006;63:205-14.
25. McGinity JW, O'Donnell PB. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev, 1997;28:25-42.
26. Miller JA, Davey RB, Oehler DD, Pound JM, George JE, Ahrens EH. Control of Boophilus annulatus (Acari: Ixodidae) on cattle using injectable microspheres containing ivermectin. J Econ Entomol, 1999;92:1142-6.
27. Miller JA, Oehler DD, Pound JM. Delivery of ivermectin by injectable microspheres. J Econ Entomol, 1998;91:655-9.
28. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release, 2008;125:193-209.
29. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents, 2008;31:91-8.
30. Palmieri GF, Cantalamessa F, Di Martino P, Nasuti C, Martelli S. Lonidamine solid dispersions: In vitro and in vivo evaluation. Drug Devel Indus Pharm, 2002;28:1241-50.
31. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solidstate solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci, 2004;93:1804-14.
32. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev, 1997;28:5-24.
33. Siepmann J, Elkharraz K, Siepmann F, Klose D. How autocatalysis accelerates drug release from PLGA-based microparticles: A quantitative treatment. Biomacromolecules, 2005;6:2312-19.
34. Sun Y, Scruggs DW, Peng Y, Johnson JR, Shukla AJ. Issues and challenges in developing long-acting veterinary antibiotic formulations. Adv Drug Deliv Rev, 2004;56:1481-96.
35. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res, 2006;23:1144-56.
36. Tracy MA, Ward KL, Firouzabadian L, Wang Y, Dong N, Qian R, Zhang Y. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials, 1999;20:1057-62.
37. Uhrich KE, Cannizzaro SM, Langer RS, ShakesheffKM. Polymeric systems for controlled drug release. Chem Rev, 1999;99:3181-98.
38. Winzenburg G, Schmidt C, Fuchs S, Kissel T. Biodegradable polymers and their potential use in parenteral veterinary drug delivery systems. Adv Drug Deliv Rev, 2004;56:1453-66.
39. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm, 2008;364:298-327.
40. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev, 2001;48:27-42.